Heart Failure and Chronic Kidney Disease Manifestation and Mortality Risk -Associations in Type 2 Diabetes: A Large Multinational Cohort Study

被引:0
|
作者
Birkeland, K. I. [1 ,2 ]
Bodegard, J. [3 ]
Eriksson, J. W. [4 ]
Norhammar, A. [5 ,6 ]
Haller, H. [7 ]
Linssen, G. C. M. [8 ]
Banerjee, A. [9 ,10 ]
Thuresson, M. [11 ]
Okami, S. [12 ]
Garal-Pantaler, E. [13 ]
Overbeek, J. [14 ]
Mamza, J. B. [15 ]
Zhang, R. [15 ]
Yajima, T. [12 ]
Komuro, I. [16 ]
Kadowaki, T. [17 ,18 ]
机构
[1] Univ Klinikum Oslo, Oslo, Norway
[2] Univ Oslo, Oslo, Norway
[3] AstraZeneca, Oslo, Norway
[4] Uppsala Univ, Klin Diabet & Stoffwechsel, Abt Med Wissensch, Uppsala, Sweden
[5] Karolinska Inst, Kardiol Fachbereich Med Solna, Stockholm, Sweden
[6] Capio St Gorans Krankenhaus, Stockholm, Sweden
[7] Hannover Med Sch, Nephrol Abt, Hannover, Germany
[8] Abt Kardiol Krankenhausgruppe Twente, Hengelo, Niederlande
[9] Coll Univ London, Inst Gesundheitsinformat, London, England
[10] Krankenhauser Coll Univ London, Abt Kardiol, London, England
[11] Statisticon AB, Uppsala, Sweden
[12] AstraZeneca, Osaka, Japan
[13] Team Gesundheit GmbH, Essen, Germany
[14] PHARMO Inst Erforschung Arzneimittelwirkungen, Utrecht, Netherlands
[15] AstraZeneca, Luton, Beds, England
[16] Med Hsch Univ Tokio, Abt Kardiovask Med, Tokyo, Japan
[17] Hsch Med Univ Tokio, Abt Pravent Diabet & Lebensstilbedingten Erkrank, Tokyo, Japan
[18] Mizonokuchi Krankenhaus Teikyo Univ, Abt Metab & Ernahrung, Teikyo, Kanagawa, Japan
来源
DIABETES STOFFWECHSEL UND HERZ | 2021年 / 30卷 / 01期
关键词
diabetic nephropathy; heart failure; macrovascular disease; observational study; type; 2; diabetes; SGLT2; inhibitor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD-free status. Results: Of 1 177 896 patients with T2D, 772 336 (66 %) were CVRD-free and followed for a mean of 4.5 years. A total of 137081 patients (18 %) developed a first CVRD manifestation, represented by CKD (36 %), HF (24 %), stroke (16 %), MI (14 %) and PAD (10 %). HF or CKD was associated with increased cardiovascular and allcause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75 - 2.33) and HR 2.05 (95 % CI 1.82 - 2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all-cause mortality risk: HRs 3.91 (95 % CI 3.02 - 5.07) and 3.14 (95 % CI 2.90 - 3.40), respectively. Conclusion: In a large multinational study of > 750 000 CVRD-free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [31] Risk of progressive chronic kidney disease in individuals with early-onset type 2 diabetes: a prospective cohort study
    Liu, Jian-Jun
    Liu, Sylvia
    Gurung, Resham L.
    Ang, Keven
    Tang, Wern Ee
    Sum, Chee Fang
    Tavintharan, Subramaniam
    Lim, Su Chi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (01) : 115 - 121
  • [32] Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease A nationwide cohort study
    Liang, Chung-Yu
    Chen, Dong-Yi
    Mao, Chun-Tai
    Hsieh, I-Chang
    Hung, Ming-Jui
    Wang, Chao-Hung
    Wen, Ming-Shien
    Cherng, Wen-Jin
    Chen, Tien-Hsing
    MEDICINE, 2018, 97 (52)
  • [33] PULMONARY HYPERTENSION IS ASSOCIATED WITH A HIGHER RISK OF HEART FAILURE AND MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: THE JACKSON HEART STUDY
    Selvaraj, Senthil
    Shah, Sanjiv
    Ommerborn, Mark
    Clark, Cheryl
    Hall, Michael
    Mentz, Robert
    Qazi, Saadia
    Robbins, Jeremy
    Chen, Jiaying
    Skelton, Thomas
    Gaziano, J. Michael
    Djousse, Luc
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1908 - 1908
  • [34] Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study
    Yen, Chieh-Li
    Wu, Chao-Yi
    See, Lai-Chu
    Li, Yi-Jung
    Tseng, Min-Hua
    Peng, Wei-Sheng
    Liu, Jia-Rou
    Chen, Yung-Chang
    Yen, Tzung-Hai
    Tian, Ya-Chung
    Yang, Chih-Wei
    Anderson, Gerard F.
    Yang, Huang-Yu
    DIABETES CARE, 2020, 43 (10) : E152 - E153
  • [35] Identification of genetic association of Thyroid Cancer with Parkinsons disease, Osteoporosis, chronic heart failure, Chronic kidney disease, Type 1 diabetes and Type 2 diabetes
    Hossain, Md Ali
    Asa, Tania Akter
    Islam, Sheikh Muhammad Saiful
    Hussain, Muhammad Sajjad
    Moni, Mohammad Ali
    2019 5TH INTERNATIONAL CONFERENCE ON ADVANCES IN ELECTRICAL ENGINEERING (ICAEE), 2019, : 832 - 837
  • [36] Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
    Bansal, Nisha
    Zelnick, Leila
    Go, Alan
    Anderson, Amanda
    Christenson, Robert
    Deo, Rajat
    Defilippi, Christopher
    Lash, James
    He, Jiang
    Ky, Bonnie
    Seliger, Stephen
    Soliman, Elsayed
    Shlipak, Michael
    Appel, Lawrence J.
    Feldman, Harold, I
    Go, Alan S.
    Lash, James P.
    Rao, Panduranga S.
    Rahman, Mahboob
    Townsend, Raymond R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (21):
  • [37] Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes - A retrospective cohort study
    Delea, TE
    Edelsberg, JS
    Hagiwara, M
    Oster, G
    Phillips, LS
    DIABETES CARE, 2003, 26 (11) : 2983 - 2989
  • [38] The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
    Lee, Seung Eun
    Yoo, Juhwan
    Kim, Bong-Seong
    Choi, Han Seok
    Han, Kyungdo
    Kim, Kyoung-Ah
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [39] The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
    Seung Eun Lee
    Juhwan Yoo
    Bong-Seong Kim
    Han Seok Choi
    Kyungdo Han
    Kyoung-Ah Kim
    Diabetology & Metabolic Syndrome, 15
  • [40] SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
    Noergaard, C.
    Torp-Pedersen, C.
    Vestergaard, P.
    Wong, N.
    Gerds, T.
    Starkopf, L.
    Bonde, A.
    Fosbol, E.
    Kober, L.
    Lee, C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 56 - 56